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Abstract
INTRODUCTION—We examined associations between magnetic resonance imaging (MRI) 
markers of cerebrovascular disease and neurodegeneration with mild cognitive impairment (MCI) 
diagnosis at baseline and conversion from normal cognition to MCI at follow-up.
METHODS—Framingham Offspring participants underwent brain MRI and neuropsychological 
assessment at baseline (n=1,049) and follow-up (n=561). Participants were classified at baseline 
and at follow-up as cognitively normal or MCI using sensitive neuropsychological criteria. White 
matter hyperintensity (WMH) volume, covert brain infarcts, hippocampal volume, and total 
cerebral brain volume were quantified.
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RESULTS—Baseline measures of WMH and hippocampal volume were associated with MCI 
status cross-sectionally and also with conversion from normal cognition to MCI at 6.5-year follow-
up. Annualized change rates in total cerebral brain volume and hippocampal volume were 
associated with conversion from normal cognition to MCI to follow-up.
DISCUSSION—Baseline WMH and hippocampal volume are markers that are both associated 
with conversion from normal cognition to MCI, highlighting the role of both vascular lesions and 
neurodegeneration in MCI.
Keywords
Mild cognitive impairment; MCI; MRI; Volumetric MRI; White matter hyperintensity; 
Hippocampal volume
INTRODUCTION
Mild cognitive impairment (MCI) was conceived to represent a transitional state between 
normal aging and Alzheimer’s disease (AD).1 MCI—even the amnestic subtype—has been 
shown to be pathologically heterogeneous and often involve co-existing cerebrovascular and 
neurodegenerative pathologies.2 In addition to established involvement of medial temporal 
neurodegeneration in MCI,3 mounting evidence suggests that cerebrovascular changes 
associated with small-vessel disease play an important role in risk and clinical expression of 
MCI and AD.4–7 Small vessel cerebrovascular disease, as reflected by white matter 
hyperintensities (WMH) (i.e., areas of increased signal on T2-weighted magnetic resonance 
imaging [MRI]), and reduced hippocampal volume have both been associated with 
decreased cognitive functioning in MCI8,9 and with faster rates of cognitive decline in MCI.5 
Less is known about how MRI biomarkers of neurodegeneration and cerebrovascular disease 
are associated with later conversion from normal cognition to MCI, particularly in 
community-based cohorts.
There is no consensus on one set of diagnostic criteria for MCI, leading to varying 
definitional schemes and prevalence rates.10 Many studies have relied on one impaired score 
(e.g., delayed free recall on story memory) to define impairment; however, reliance on a 
single neuropsychological test as a marker of impairment is problematic given that a single 
impaired score within a cognitive battery is common in neurologically normal adults.11 
Research has emerged suggesting that actuarial neuropsychological criteria utilizing 
comprehensive neuropsychological protocols to assess a wide range of cognitive abilities 
beyond memory improves diagnostic rigor.12 Our previous work using actuarial criteria to 
diagnosis MCI suggest that two impaired scores, defined as <1 SD below normative 
expectations, within a cognitive domain10 bolsters associations between MCI status and 
biomarkers while decreasing false positive errors compared with more conventional 
approaches.12
In the current study, we examined associations of MRI markers of cerebrovascular disease 
(WMH volume, covert brain infarcts) and neurodegeneration (hippocampal volume, total 
cerebral volume) with MCI diagnosis using actuarial neuropsychological criteria in the 
Framingham Offspring Cohort. In addition, we examined the extent to which baseline MRI 
Bangen et al. Page 2
Alzheimer Dis Assoc Disord. Author manuscript; available in PMC 2019 January 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
markers are associated with conversion to MCI and the degree to which change in MRI 
markers from baseline to follow-up is associated with conversion to MCI. Given the well-
established involvement of medial temporal lobe structures in MCI and AD, we expected 
that hippocampal volume would be associated with MCI status. Considering growing 
evidence of the role of small-vessel cerebrovascular disease in MCI and AD5,13, we 
additionally hypothesized that WMH volume would also be associated with conversion to 
MCI.
METHODS
Participants
The Framingham Heart Study (FHS) is a community-based, prospective study initiated in 
1948 to identify cardiovascular disease risk factors. Participants in the current study were 
members of the Offspring Cohort, which includes biological children of the original FHS 
cohort and offspring spouses (n=5,124) who have undergone health examinations 
approximately every 4 years since 1971. The present analysis is based on the 3,539 
participants who attended the 7th Offspring examination. As part of an ancillary study, 
participants were invited to undergo neuropsychological assessment and brain MRI (1999–
2005). 2,551 participants who attended the 7th examination also underwent 
neuropsychological assessment. As MCI prevalence is low in younger adults, we restricted 
our sample to the 1,422 participants aged ≥60 years at the time of neuropsychological 
testing. Of these, 1,215 participants also completed a MRI scan contemporaneously with the 
7th examination cycle. We excluded participants with prevalent dementia (n=14), prevalent 
stroke (n=28), or incomplete neuropsychological data (n=111), resulting in a final sample 
size of 1,049 for cross-sectional analysis (supplementary figure 1).
For longitudinal analysis, we included the 813 participants from the cross-sectional analysis 
who were free of MCI at baseline. Of these, 665 participants underwent a repeat 
neuropsychological test contemporaneously (within 1 year before and 5 years after) with the 
8th Framingham Offspring examination cycle (2005–2008). We excluded participants due to 
prevalent dementia (n=14), stroke (n=13), and other neurological conditions (n=9) at follow-
up neuropsychological testing, and incomplete neuropsychological data (n=68), resulting in 
a final sample size of 561 participants for longitudinal analysis (supplementary figure 2).
The protocol was approved by the Institutional Review Board of Boston University Medical 
Center. All participants provided written informed consent.
Neuropsychological Assessment
Standardized neuropsychological tests were administered at baseline and follow-up. Based 
on the administered battery, there were three cognitive domains in which there were at least 
two tests in that domain, which is necessary for MCI classification as described below and 
as previously published in this sample.14 Memory was assessed with Wechsler Memory 
Scale (WMS) Logical Memory delayed recall and recognition and Visual Reproduction 
delayed recall and recognition. Executive Functioning/Attention/Processing Speed was 
measured by Trail Making Tests A and B. Language was assessed with the Boston Naming 
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Test and Similarities from the Wechsler Adult Intelligence Scale. Neuropsychological tests 
scores were regressed onto age and education within gender. Residuals from these 
regressions were standardized to have a mean of zero and a standard deviation of one using 
z-score transformations.
MCI Classification
Participants were classified as normal or MCI according to comprehensive 
neuropsychological criteria that operationalizes impairment as performance falling greater 
than one standard deviation below normative expectations on at least two measures within a 
cognitive domain.10 Participants were classified as Amnestic MCI when memory was 
impaired and Non-Amnestic MCI when non-memory domain(s) was impaired.
Neuroimaging
MRI methods have been described in detail.15–17 Briefly, participants were imaged on a 1 or 
1.5 Tesla Siemens Magnetom MRI scanner (see supplementary methods online). Three-
dimensional T1 and double echo proton density and T2 coronal images were acquired in 4-
mm contiguous slices. Images were analyzed with semi-automated segmentation methods 
that have been previously described.16 Manual tracing was performed to determine total 
intracranial volumes. Hippocampal and cerebral volumes were determined using automated 
procedures described below.
Hippocampal volume was computed using a standard atlas based diffeomorphic approach18 
with label refinement modifications. Harmonized hippocampal masks developed through the 
European Alzheimer’s Disease Consortium (EADC) and Alzheimer’s Disease 
Neuroimaging Initiative (ADNI) Working Group on the Harmonized Protocol for Manual 
Hippocampal Segmentation were used with the following procedures: 1) pre-processing with 
extraction of intracranial cavity, non-uniformity correction, and tissue classification;19 2) 
atlas registration of EADC-ADNI hippocampal masks;20 3) atlas fusion utilizing Multi-Atlas 
Label Fusion;21 and 4) intensity-based label refinement.
To segment WMH from other brain tissues, the first and second echo images from T2 
sequences were summed and a log-normal distribution was fitted to the summed data (after 
removal of CSF and correction of image intensity non-uniformities).22 A segmentation 
threshold for WMH of 3.5 SD in voxel intensity greater than the mean of the fitted 
distribution of brain parenchyma was applied.17 Brain infarcts were defined as areas of 
abnormal signal intensity in a vascular distribution; 3mm or larger in size; with a CSF 
density on the subtraction image (proton density minus T2 image); and for lesions in the 
basal ganglia, distinct separation from the circle of Willis vessels.16,23
Statistical Analyses
Descriptive statistics were calculated using means and SDs, medians and interquartile 
ranges, and frequency counts and percent. Continuous MRI measures were standardized to a 
mean of zero and a SD of one to facilitate comparisons between measures. Natural log 
transformation was used to improve distribution normality of WMH volume. MRI variables 
were examined as both continuous and ordinal variables. Ordinal variables were examined 
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given the possibility of nonlinear relationships between MRI variables and cognitive status/
cognitive outcome. For total cerebral brain volume and hippocampal volume, those in the 
bottom quartile (with the smallest total cerebral brain volume and the smallest hippocampal 
volume, respectively) were compared with those from the top three quartiles. For WMH 
volume, those in the top quartile (with the greatest WMH volume) were compared with 
those from the three bottom quartiles. Covert brain infarcts were categorized as present or 
absent. Annualized change in MRI brain measures was calculated as the difference between 
the raw MRI volumes from baseline to follow-up, divided by the follow-up period in years.
Logistic regression models examined associations between MRI brain measures and 
presence of MCI at baseline and follow-up. Logistic regression was used rather than survival 
analysis given there were two time points for the MRI and neuropsychological data. Our 
primary models were adjusted for age at MRI, years between MRI and neuropsychological 
testing, education group (<high school degree, high school degree, some college, ≥college 
degree), APOE ε4 status (carrier versus noncarrier), vascular risk factors (systolic blood 
pressure, hypertension treatment, diabetes, current smoking, history of cardiovascular 
disease and history of atrial fibrillation), and all other MRI variables. All models that 
examined annualized change in MRI measures adjusted for the same variables as the logistic 
regression analyses for baseline MRI variables described above and additionally adjusted for 
baseline MRI measures. We additionally constructed models adjusted for demographics only 
and adjusted for demographics, APOE ε4 status, and vascular risk factors (presented in the 
online supplement). Overall, results from these models were similar to results from fully 
adjusted models presented in our primary analysis. In addition, analyses were conducted 
assessing whether there was an interaction between WMH volume and hippocampal volume 
on presence of MCI or conversion from normal cognition to MCI. Secondary analyses were 
performed restricting the MCI group to only those with amnestic MCI. In addition, brain 
MRI were acquired using different MRI machine types that included differences in field 
strength (i.e., 1 Tesla and 1.5 Tesla) and analyses were performed to assess the potential 
confounding effects of these differences on MRI quantification. All analyses were performed 
with Statistical Analyses System software version 9.4 (SAS Institute, Cary, NC). A p-value 
of <0.05 was considered statistically significant.
RESULTS
Participant characteristics
Participant characteristics are presented in Table 1. At baseline, 22.5% of participants were 
classified as MCI (17.4% amnestic MCI, 5.1% non-amnestic MCI). Longitudinal analyses, 
which included those participants who were free of MCI at baseline, demonstrated that at 
follow-up (average 6.5 years after baseline) 13.5% of participants had new onset MCI (9.8% 
amnestic MCI, 3.7% non-amnestic MCI).
Cross-sectional associations of MRI markers with MCI
Table 2 presents cross-sectional associations between each MRI brain measure and MCI 
status at baseline adjusting for demographic variables, APOE ε4 status, vascular risk factors, 
and all other MRI measures. Being in the top quartile for WMH volume was associated with 
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48% higher odds of MCI at baseline (OR=1.48, 95% CI:1.03–2.12, p-value=0.03). When the 
MCI group was restricted to those with amnestic MCI, the odds ratio remained similar to 
that observed for any MCI but the statistical significance was attenuated (p-value=0.05). 
When WMH volume was examined as a continuous variable, there were trends toward 
greater WMH volume being associated with higher odds of MCI (p-values ranged from 0.09 
to 0.12).
Being in the bottom quartile of hippocampal volume was associated with 58% higher odds 
of MCI (OR=1.58, 95% CI:1.12–2.24, p-value=0.01) and 80% higher odds of MCI when the 
MCI group was restricted to those with amnestic MCI (OR=1.80, 95% CI:1.23–2.64, p-
value=0.002). Similarly, when examined continuously, lower hippocampal volume was 
significantly associated with higher odds of MCI. Neither total cerebral brain volume 
(continuously or as quartiles) nor presence of covert brain infarcts were associated with the 
presence of MCI at baseline. There was no interaction between WMH volume and 
hippocampal volume on presence of MCI at baseline (p=0.99).
Longitudinal associations of baseline MRI markers with conversion to MCI at follow-up
Table 3 shows the association between baseline MRI and conversion from normal cognition 
to MCI at follow-up adjusting for demographic variables, APOE ε4 status, vascular risk 
factors, and all other MRI measures. Higher WMH volume (being in the top quartile) at 
baseline was associated with higher odds of conversion to MCI (OR=2.04, 95% CI:1.09–
3.79, p-value=0.03). When the MCI group was restricted to those with amnestic MCI, 
findings were no longer statistically significant. When examined as a continuous variable, 
baseline WMH volume was not associated with conversion to MCI at follow-up. Being in 
the bottom quartile of hippocampal volume was associated with higher odds of MCI 
(OR=2.13, 95% CI:1.14–3.96, p-value=0.02) and findings remained similar then the MCI 
group was restricted to those with amnestic MCI only (OR=2.60, 95% CI:1.29–5.23, p-
value=0.007). Similarly, when examined continuously, lower hippocampal volume was 
significantly associated with higher odds of MCI. Results remained similar when the MCI 
group was restricted to those individuals with amnestic MCI. Total cerebral brain volume 
(either continuously or as quartiles) and presence of brain infarcts were not associated with 
conversion from normal cognition to MCI at follow-up. There was no significant interaction 
between WMH volume and hippocampal volume on conversion to MCI at follow-up 
(p=0.06).
Longitudinal associations of change in MRI markers between baseline and follow-up with 
conversion to MCI at follow-up
Table 4 presents longitudinal associations between annualized change in MRI brain 
measures between baseline and follow-up and conversion to MCI adjusting for age at MRI, 
years between baseline MRI and follow-up neuropsychological testing, education group, 
APOE ε4 status, vascular risk, baseline MRI measures, and all other MRI measures. Change 
in total cerebral brain volume, both continuously and as quartiles, was significantly 
associated with conversion from normal cognition to MCI although findings were attenuated 
when the MCI group was restricted to those with amnestic MCI. Change in continuous 
hippocampal volume was associated with conversion to MCI when the MCI group was 
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restricted to those with amnestic MCI (OR=0.68, 95% CI:0.48–0.96, p-value=0.03). There 
were no significant associations between conversion from normal cognition to MCI and 
annualized change in hippocampal volume as quartiles or WMH volumes (continuously or 
as quartiles). The interaction between change in WMH volume and hippocampal volume on 
conversion to MCI at follow-up was not significant (p=0.88).
Analyses to Examine Potential Bias across MRI Scanners and Field Strengths
Brain MRI were acquired using different MRI machine types that included differences in 
field strength (1 Tesla versus 1.5 Tesla). To assess the potential confounding effects of these 
differences on MRI quantification, MRI machine, operating system and field strength were 
added to age and gender estimates as predictors of the quantitative MRI measures included 
in this study for all Framingham subjects studied during the period of observation of this 
study. Adjusting for the multiple comparisons across regions, no significant effects of MRI 
machine, operating system or field strength was found.
DISCUSSION
We found that baseline WMH and hippocampal volume were associated with presence of 
MCI at baseline and associated with conversion from normal cognition to MCI at follow-up. 
Annualized change from baseline to follow-up in total cerebral brain and hippocampal 
volumes, but not WMH volume, was associated with conversion to MCI. This pattern of 
findings raises the possibility that both cerebrovascular and neurodegenerative changes play 
prominent roles prior to the development of frank cognitive impairment whereas 
neurodegeneration may continue to play a larger role more proximal to conversion to MCI. 
This pattern of findings is consistent with models and data indicating that cerebrovascular 
changes, including WMH, play an important early role in individuals at risk for dementia5,24 
as well as neuropathological data suggesting that AD-related neurodegeneration initially 
occurs in MTL structures and progresses to more global involvement over time.3 Future 
studies with additional time points are necessary to more fully examine this possibility.
Although we found that baseline WMH volume was associated with baseline MCI status and 
conversion from normal cognition to MCI at follow-up, we did not find associations between 
increased WMH volume over time and higher odds of conversion to MCI. This contrasts 
with other studies which have found that increased progression of WMH volume is 
associated with conversion to MCI.25,26 Compared to the current study, participants in these 
previous studies were older at baseline (mean age in 80s versus 60s), the follow-up period 
was longer, and baseline WMH volume was higher. Differences in cohort characteristics and 
study design may explain discrepancies in findings. Nonetheless, findings from these 
previous studies and the current study provide support for the notion that WMH volume may 
be useful in determining those at risk for later cognitive impairment and may inform 
treatment strategies that would be useful prior to dementia onset.
In the current study, the effect of WMH was somewhat reduced when treating this variable 
continuously rather than categorically suggesting the presence of a nonlinear relationship 
whereby increased risk of MCI was particularly evident when comparing those in the 
highest quartile of WMH volume compared to all other participants. This observation is 
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consistent with other studies, including previous research from the FHS, indicating that 
extensive WMH volume in particular may relate to decreased cognitive functioning.27 In 
addition, for cross-sectional and longitudinal models the effect of WMH was attenuated 
when the analyses where restricted to amnestic MCI whereas hippocampal volume was 
significantly associated with MCI status in the whole sample as well as when the MCI 
sample was restricted to amnestic MCI. This pattern of findings may relate to reduced 
power. Amnestic and non-amnestic MCI have been linked to different underlying etiologies 
although it should be noted that amnestic MCI is not specific to a pre-AD condition and 
vascular disease has been associated with memory impairment. Findings related to WMH 
have been mixed with some studies demonstrating that non-amnestic MCI subgroups have 
greater WMH volume relative to MCI subgroups characterized by memory deficits6 whereas 
other studies have found that amnestic MCI subgroups show greater WMH burden relative 
to non-amnestic MCI.28 Other studies have provided evidence for a threshold effect whereby 
small-vessel cerebrovascular disease may induce specific patterns of cognitive impairment.7 
Given the small number of participants characterized as non-amnestic MCI, we did not 
conduct separate analyses for this subtype.
Although MCI is associated with greater vascular risk burden29 and small-vessel 
cerebrovascular disease,6,30 prevailing models of AD pathogenesis31 and proposed research 
biomarkers of MCI32 do not yet formally integrate either MRI evidence of cerebrovascular 
disease or cerebrovascular risk factors in their models or conceptualizations. Although there 
are no widely accepted criteria for determining biomarker positivity for cerebrovascular 
disease, there is a need to develop such methodologies. A metric has recently been proposed 
to identify participants with cerebrovascular imaging abnormalities based on a combination 
of infarcts and WMH burden in the context of absence or presence of amyloid elevation.33 
Further research is needed to clarify the link between small-vessel cerebrovascular disease 
and MCI, particularly in light of evidence that vascular changes may precede neuronal 
dysfunction and may initiate and exacerbate neurodegeneration.24,34 Our work has shown 
that small-vessel cerebrovascular disease increases AD risk,13 relates to heterogeneity 
among MCI phenotypic subgroups,6,28 predicts disease course in prodromal dementia,5 and 
is more reliably associated with markers of neurodegeneration than are measures of Aβ.35 
Whether or not WMH represents a pathogenic factor of AD per se, it is clear that small-
vessel cerebrovascular disease is an important component of the clinical expression of the 
disease, which has implications not only for models of AD pathophysiology and diagnostic 
criteria but also for treatment.13 Given that traditional vascular risk factors are known risk 
factors for the development of WMH pathology, aggressive efforts to prevent and manage 
these risk factors may reduce risk for MCI and AD.
We excluded individuals with clinical stroke, suggesting that even subclinical 
cerebrovascular changes play an important role in the expression and evolution of MCI. The 
notion is in line with our previous work showing that, in a sample of autopsy-confirmed AD 
patients, the presence of mild cerebrovascular changes was associated with less severe AD 
pathology yet there were no differences in severity of cognitive impairment between the AD 
patients with and without evidence of cerebrovascular disease.36 These findings raise the 
possibility that cerebrovascular pathology contributes to overall severity of cognitive 
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impairment, even in patients with autopsy-confirmed AD and relatively mild cerebrovascular 
disease.36
The lack of consensus for defining MCI may contribute to uncertainty regarding the optimal 
biomarkers for prodromal AD. Our previous work showing that actuarial clinical diagnostic 
decision-making using a full range of neuropsychological test measures provides more 
nuanced MCI distinctions and leads to tighter associations with respect to biomarkers related 
to cognitive impairment as well as progression to dementia.37 In the current study, we 
applied rigorous actuarial MCI criteria and MCI conversion was associated with MRI 
markers of small vessel cerebrovascular disease, providing further support for the 
involvement of WMH in MCI.
Strengths of the current study include the large, well-characterized, community-based 
sample; prospective study design; and ongoing follow-up for several years. The present 
findings extend previous FHS results showing associations of WMH volume with decreased 
cognitive performance27 and incident MCI38 by incorporating rigorous actuarial 
neuropsychological criteria for MCI, excluding those with history of clinical stroke or 
dementia, examining longitudinal change in MRI volume, and including MRI markers of 
neurodegeneration (i.e., hippocampal volume). We found that baseline measures of both 
WMH volume and hippocampal volume contributed to new onset MCI.
There are limitations to the present findings. We assessed two MRI markers of 
cerebrovascular changes and neurodegeneration each and did not examine additional 
markers that may relate to MCI (e.g., microinfarcts, tau, cortical thickness). A recent 
multimodal study suggested that the influence of WMH volume on cognition may be 
mediated by clinically covert processes, such as microinfarcts.39 In addition, hippocampal 
volume has been associated with non-neurodegenerative pathologies including subcortical 
cerebrovascular disease.40 Future research integrating additional markers of 
neurodegeneration such as AD-related patterns of cortical thickness may be more specific to 
neurodegeneration than hippocampal volume alone. Notably, participants included in the 
longitudinal study sample were younger, had completed more education, and had lower 
vascular risk burden than those who were not included in the longitudinal sample and who 
were also free of MCI at baseline (Table s1). Despite heterogeneity in cognitive 
characterization, our sample was generally well-educated, medically healthy, and had 
relatively low WMH burden, which may have attenuated our ability to detect group 
differences. The magnitude of effects of our findings may have differed in a sample with 
greater vascular risk, use of a T2-weighted fluid attenuated inversion recovery (FLAIR) to 
quantify WMH, and a more heterogeneous group of MCI participants that did not include 
predominantly amnestic MCI. For instance, we found trends toward associations between 
the presence of covert brain infarcts and MCI at baseline as well as conversion from normal 
cognition to MCI at follow-up. These associations may have been statistically significant in 
a cohort with greater burden of cerebrovascular disease.
Despite these limitations, in the search for reliable biomarkers of MCI and dementia risk, in 
addition to assessment of medial temporal lobe volume and neurodegeneration, 
consideration of WMH may prove useful. The combination of white matter markers with 
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additional biomarkers (e.g., CSF amyloid, hippocampal volume) as well as consideration of 
MCI clinical subtypes (e.g., amnestic, non-amnestic) may more completely inform the AD 
and cerebrovascular contributions to the dementia prodrome. In summary, our results show 
that small-vessel cerebrovascular disease increases risk for MCI, a known risk factor for 
subsequent transition to dementia. Our findings suggest that hippocampal atrophy and 
WMHs are useful biomarkers associated with conversion to MCI. Our findings extend 
earlier results highlighting the association between WMH and risk of AD to conversion from 
normal cognition to MCI.
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Refer to Web version on PubMed Central for supplementary material.
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Table 1
Participant characteristics
Cross-Sectional Study Samplea
(N=1049)
Longitudinal Study Sampleb
(N=561)
Continuous characteristics, mean (SD)
Age at baseline MRI (years) 68.6 (5.7) 67.8 (5.4)
Systolic blood pressure (mm Hg) 131 (19) 129 (18)
Continuous characteristics, median (25th, 75th percentile)
Days between baseline MRI and baseline neuropsychological 
assessment
0.0 (0.0, 0.0) —
Years between baseline MRI and follow-up neuropsychological 
assessment
— 6.5 (6.0, 6.9)
Days between follow-up MRI and follow-up neuropsychological 
assessment
— 0.0 (0.0, 0.0)
Years between baseline MRI and follow-up MRI — 6.5 (5.9, 6.9)
Categorical characteristics, n (%)
Women 556 (53.0) 306 (54.6)
Education Group
 <High school degree 43 (4.1) 15 (2.7)
 High school degree 336 (32.0) 173 (30.8)
 Some college 322 (30.7) 171 (30.5)
 ≥College degree 348 (33.2) 202 (36.0)
APOE ε4 allele 225 (21.9) 120 (21.8)
Diabetes 144 (14.0) 57 (10.3)
Current smoker 84 (8.0) 32 (5.7)
Hypertension treatment 422 (40.2) 199 (35.5)
History of cardiovascular disease 152 (14.5) 65 (11.6)
History of atrial fibrillation 52 (5.0) 19 (3.4)
Any MCI diagnosis at baseline 236 (22.5) 0 (0.00)
 Amnestic MCI 183 (17.4) 0 (0.00)
 Non-Amnestic MCI 53 (5.1) 0 (0.00)
Any MCI diagnosis at follow-up — 72 (12.8)
 Amnestic MCI — 52 (72.2)
 Non-Amnestic MCI — 20 (27.8)
MRI measures at baseline, median (25th percentile, 75th percentile)
Total cranial volume (cm3) 1239 (1148, 1332) 1239 (1151, 1337)
Total cerebral brain volume (%) 78.3 (76.2, 80.4) 78.7 (76.8, 80.6)
White matter hyperintensities volume (%) 0.067 (0.036, 0.13) 0.060 (0.035, 0.11)
Hippocampal volume (%) 0.53 (0.49, 0.56) 0.53 (0.50, 0.56)
Covert brain infarct (present), n (%) 133 (12.7) 61 (10.9)
Annualized change in MRI measures between baseline and follow-up, 
median (25th percentile, 75th percentile)
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Cross-Sectional Study Samplea
(N=1049)
Longitudinal Study Sampleb
(N=561)
Total cerebral brain volume (cm3/year) — −7.02 (−9.53, −4.24)
White matter hyperintensities volume (cm3/year) — 0.15 (0.052, 0.33)
Hippocampal volume (cm3/year) — −0.010 (−0.035, 0.013)
aCross-sectional analysis includes participants who have MRI and neuropsychological data at baseline.
b
Longitudinal analysis includes participants who were free of MCI at baseline and had neuropsychological data available at follow-up.
Note that MRI variables expressed as percent are normalized by total intracranial volume to correct for head size.
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in
uo
us
(P
er 
SD
 in
cre
me
nt)
a
0.
64
 (0
.46
–0
.88
)
0.
00
7
0.
73
 (0
.52
–1
.03
)
0.
07
Q1
 vs
 Q
23
4
3.
03
 (1
.50
–6
.10
)
0.
00
2
2.
69
 (1
.20
–5
.99
)
0.
02
Ln
 w
hi
te
 m
at
te
r h
yp
er
in
te
ns
iti
es
 v
o
lu
m
e 
(cm
3 /y
ea
r)
Co
nt
in
uo
us
(P
er 
SD
 in
cre
me
nt)
a
0.
94
 (0
.69
–1
.27
)
0.
69
0.
92
 (0
.67
–1
.28
)
0.
63
Q4
 vs
 Q
12
3
1.
33
 (0
.67
–2
.65
)
0.
42
1.
17
 (0
.54
–2
.53
)
0.
70
H
ip
po
ca
m
pa
l v
o
lu
m
e 
(cm
3 /y
ea
r)
Co
nt
in
uo
us
(P
er 
SD
 in
cre
me
nt)
a
0.
77
 (0
.56
–1
.04
)
0.
09
0.
68
 (0
.48
–0
.96
)
0.
03
Q1
 vs
 Q
23
4
1.
31
 (0
.66
–2
.60
)
0.
44
1.
64
 (0
.77
–3
.49
)
0.
20
M
od
el
s a
re
 a
dju
ste
d f
or 
ag
e a
t M
RI
, se
x
, 
ye
ar
s b
et
w
ee
n 
ba
se
lin
e 
M
RI
 a
nd
 fo
llo
w
-u
p 
ne
ur
op
sy
ch
ol
og
ic
al
 a
ss
es
sm
en
t, 
ed
uc
at
io
n 
gr
ou
p 
(<
hig
h s
ch
oo
l d
eg
re
e,
 h
ig
h 
sc
ho
ol
 d
eg
re
e,
 so
m
e 
co
lle
ge
, ≥
co
lle
ge
 
de
gr
ee
), A
PO
E 
ε4
 st
at
us
 (c
arr
ier
 ve
rs
u
s 
n
o
n
ca
rr
ie
r),
 va
sc
u
la
r r
isk
 fa
ct
or
s 
(sy
sto
lic
 bl
oo
d p
res
su
re,
 hy
pe
rte
ns
io
n 
tre
at
m
en
t, 
di
ab
et
es
, s
m
ok
in
g,
 h
ist
or
y 
of
 c
ar
di
ov
as
cu
la
r d
ise
as
e,
 h
ist
or
y 
of
 a
tri
al
 fi
br
ill
at
io
n),
 
ba
se
lin
e 
br
ai
n 
M
RI
 v
o
lu
m
e,
 a
nd
 th
e 
ot
he
r M
RI
 m
ea
su
re
s (
co
nti
nu
ou
s) 
lis
ted
 in
 th
e t
ab
le.
a S
ta
nd
ar
d 
de
v
ia
tio
n 
in
cr
em
en
t c
al
cu
la
te
d 
us
in
g 
th
e 
en
tir
e 
sa
m
pl
e
N
ot
e:
 A
nn
ua
liz
ed
 c
ha
ng
e 
in
 M
RI
 b
ra
in
 m
ea
su
re
s w
as
 c
al
cu
la
te
d 
as
 th
e 
di
ffe
re
nc
e 
be
tw
ee
n 
th
e 
ra
w
 M
R
I v
o
lu
m
es
 fr
om
 b
as
el
in
e 
to
 fo
llo
w
-u
p,
 d
iv
id
ed
 b
y 
th
e 
fo
llo
w
-u
p 
pe
rio
d 
(in
 ye
ars
). I
nd
ivi
du
al
s w
ith
 M
CI
 
at
 b
as
el
in
e 
ar
e 
ex
cl
ud
ed
 fr
om
 th
e 
an
al
ys
is.
 In
 a
dd
iti
on
, 7
0 
pa
rti
ci
pa
nt
s f
ro
m
 th
e 
lo
ng
itu
di
na
l s
tu
dy
 sa
m
pl
e 
di
d 
no
t c
om
pl
et
e 
a 
fo
llo
w
-u
p 
M
RI
 a
nd
 th
us
 w
er
e 
no
t i
nc
lu
de
d 
in
 th
e 
an
al
ys
is 
of
 a
nn
ua
liz
ed
 c
ha
ng
e 
in
 M
RI
 m
ea
su
re
s.
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